ABCG2 and head and neck cancer: We found that two of five gefitinib-resistant head and neck cancer cell lines [27], including FaDu, and OECM-1 cell lines, express significant levels of BCRP/ABCG2 protein but was not detected in two gefitinib-sensitive HSC3 and SCC-9 cell lines (Fig. 4B).